Prescient Therapeutics Shareholder Replay 9th February 2023

February 9, 2023

Prescient Therapeutics Shareholder Briefing

In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:

  • Prescient’s diversified portfolio of both later stage and emerging assets for cancer treatment
  • Our lead targeted therapy, PTX-100, which is exhibiting promising data in a disease of unmet need
  • The potential significance of accelerating clinical development of PTX-100 in an orphan disease
  • How our OmniCAR and CellPryme cell therapy platforms allow us to partner with any CAR-T developer, giving us a ‘shovels to the gold rush’ position

Recorded on 9 February 2023 at 11:00am (AEDT)

Join the next Prescient Therapeutics webcast

Register to stay up to date with Prescient Therapeutics

Featured Speakers

Steven Yatomi-Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.

Related Post

×